Protonated form: the potent form of potassium-competitive acid blockers.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 24845980.
- Also identified by DOI 10.1371/journal.pone.0097688 and PMC identifier 4028304.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Potassium-competitive acid blockers (P-CABs) are highly safe and active drugs targeting H+,K+-ATPase to cure acid-related gastric diseases. In this study, we for the first time investigate the interaction mechanism between the protonated form of P-CABs and human H+,K+-ATPase using homology modeling, molecular docking, molecular dynamics and binding free energy calculation methods. The results explain why P-CABs have higher activities with higher pKa values or at lower pH. With positive charge, the protonated forms of P-CABs have more competitive advantage to block potassium ion into luminal channel and to bind with H+,K+-ATPase via electrostatic interactions. The binding affinity of the protonated form is more favorable than that of the neutral P-CABs. In particular, Asp139 should be a very important binding site for the protonated form of P-CABs through hydrogen bonds and electrostatic interactions. These findings could promote the rational design of novel P-CABs.
Medical subject headings
- H(+)-K(+)-Exchanging ATPase
- Molecular Docking Simulation
- Potassium
- Potassium Channel Blockers
- Protons